3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Neoplasms
1
Leukemia, Myeloid, Acute
1
Leukemia, Biphenotypic, Acute
1
Leukemia
1
Interventions
fludarabine phosphate
4
fludarabine
3
Mycophenolic Acid
3
Filgrastim
3
Cytarabine
3
Cyclophosphamide
3
revumenib
2
Whole-Body Irradiation
2
Mesna
2
Bone Marrow Transplantation
2
pegaspargase
1
Vincristine
1
Thiotepa
1
Stem Cell Transplantation
1
Standard of Care
1
Sirolimus
1
Midazolam
1
Melphalan
1
MRX-2843
1
Itraconazole
1
Granulocyte Colony-Stimulating Factor
1
Fentanyl
1
Dexamethasone
1
Cyclosporine
1
Cord Blood Stem Cell Transplantation
1
Cobicistat
1
Busulfan
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Leukemia, Biphenotypic, Acute
×
Cobicistat
×
Clear all
NCT04065399
2026-03-18
AUGMENT-101
Syndax Pharmaceuticals
Phase 1/2
Recruiting
447 enrolled
2 FDA